logo
41-Year-Old Longevity Doctor Claims His Biological Age Is 24, Reveals 3 Supplements He Takes

41-Year-Old Longevity Doctor Claims His Biological Age Is 24, Reveals 3 Supplements He Takes

NDTV11-06-2025
A 41-year-old London-based primary care doctor has claimed his biological age is 24, thanks to his comprehensive routine and supplement regimen. According to tests taken 18 months ago, Dr. Mohammed Enayat's biological age was 17 years younger than his chronological age. He used GlycanAge and TruAge PACE tests, which measure inflammation and epigenetics, to determine his biological age.
Notably, Dr. Enayat, founder of Hum2n longevity clinic, has tracked his health for seven years using wearables like Oura ring and Whoop strap, along with regular blood, urine, and microbiome tests. Based on the results, he adjusts his longevity routine, including supplements. His core supplements include daily cycles of B complex, folate, magnesium, and omega-3 fatty acids.
"While I believe these supplements have supported my biological age reversal, I credit them as one component in a much broader framework," Mr Enayat told Business Insider.
1. Vitamin B complex
Dr. Enayat said he takes vitamin B complex and folate supplements due to a methylation gene defect that causes elevated homocysteine levels, increasing his risk of blood clots, heart attack, and stroke. The supplements help lower these levels. Generally, dietitians recommend obtaining nutrients through food and supplementing only when necessary, such as in cases of deficiency or inability to consume certain nutritious foods. Foods rich in B vitamins, like fish, poultry, legumes, and leafy greens, can also help reduce homocysteine levels.
Research suggests B vitamins may be linked to improved mood and dementia prevention, but further studies are required to confirm these findings.
"Even without a methylation-related gene defect, I would still consider taking a methylated B complex, particularly during periods of high stress, poor sleep, or intensive training, as these increase the demand for B vitamins," Mr Enayat said.
2. Magnesium
Dr. Enayat takes magnesium bisglycinate due to his naturally low magnesium levels from dietary intake. This form is chosen for its better absorption, helping to boost his levels. Magnesium is essential for bone health, blood sugar regulation, and muscle function, and can also be found in foods like legumes and leafy greens.
He reported that taking magnesium helps reduce muscle aches and improves his sleep, allowing him to fall asleep more easily.
3. Omega-3 Fatty Acids
Dr. Enayat takes a daily omega-3 supplement due to his naturally low levels. Omega-3s, found in oily fish, walnuts, and chia seeds, support heart health, reduce inflammation, and lower blood pressure. While eating fatty fish weekly is proven to protect against cardiovascular disease, the benefits of supplement form are less clear. However, some research suggests omega-3 supplements may have anti-ageing effects, with a recent study finding participants who took omega-3s daily had lower biological ages.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Study analyses intake of ultra-processed foods among South Asian countries
Study analyses intake of ultra-processed foods among South Asian countries

News18

timean hour ago

  • News18

Study analyses intake of ultra-processed foods among South Asian countries

New Delhi, Jul 21 (PTI) A study that analysed intake of ultra-processed foods among South Asians found that three-fourths of those living in Bangladesh, Sri Lanka, and north India reported consuming these foods in the 24 hours prior to the survey. Researchers from the University of Cambridge in the UK, the Madras Diabetes Research Foundation in Chennai, and institutes in Pakistan, Bangladesh and Sri Lanka looked at the relation between consuming ultra-processed foods and sociodemographic factors of participants. The findings, published in The Lancet Regional Health Southeast Asia journal, also show that 41 per cent of participants from south India and Pakistan reported having consumed ultra-processed foods in the 24 hours prior to being surveyed. These foods involve extensive industrial processing and additives such as added sugars, and are known to heighten risk of obesity, metabolic and cardiovascular conditions. Data of over 60,700 adults living in Bangladesh, Pakistan, Sri Lanka and India were analysed. The participants were recruited for the South Asia Biobank, a UK-based long-term study designed to understand reasons contributing to the high risk of life threatening conditions such as heart disease, type 2 diabetes and obesity among South Asians. Across the four regions studied, ultra-processed foods were found to account for 13-17 per cent of one's total energy intake, with biscuits being a common source. Further, younger age was a factor linked with consuming ultra-processed foods in Pakistan and Sri Lanka, and older age in Bangladesh and north India — and women across most regions were more likely to consume these foods. Consumption also was found to be lower among married people or those living together across the regions studied, compared to those who were single. The researchers said a 2023 study that examined the link between consuming ultra-processed foods and sociodemographic factors analysed data from 32 countries, but 'revealed a significant evidence gap with no studies conducted in South Asian countries". 'This is the first study to assess the sociodemographic correlates of (ultra-processed foods) consumption in South Asia, using individual-level dietary recall data in a large population-based study of South Asian adults," according to the study. 'In Bangladesh, Sri Lanka, and North India, (nearly) 75 per cent of participants reported consuming (ultra-processed foods) during the previous day, versus 41 per cent in south India and Pakistan," it said. They added that the study's results provide valuable insights for developing targeted interventions. The South Asia Biobank is based at Imperial College London and funded by the UK's National Institute for Health Research. PTI KRS RHL view comments First Published: July 21, 2025, 14:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

MedGenome raises USD 47.5 mn in Series E funding round
MedGenome raises USD 47.5 mn in Series E funding round

News18

time2 hours ago

  • News18

MedGenome raises USD 47.5 mn in Series E funding round

New Delhi, Jul 21 (PTI) Genomic diagnostics and research services company MedGenome on Monday said it has raised USD 47.5 million (over Rs 409 crore) in Series E funding round from private equity firm Maj Invest and existing investor Novo Holdings. The round also saw participation from Sofina, an existing shareholder in the company, the Bengaluru-based firm said in a statement. The funding will enable the company to broaden access to its genomics and integrated diagnostics solutions across India and other emerging markets, it added. 'This fundraise also reflects the growing adoption of genomics in personalised and preventive healthcare in India as well as other emerging economies," MedGenome CEO Vedam Ramprasad said. MedGenome offers over 1,300 high-end genetic tests across major disease categories – oncology, inherited diseases, reproductive diseases, infectious diseases, and preventive wellness. PTI MSS MSS SHW Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

ADIA to invest $200 million in Gujarat-based medtech co Meril
ADIA to invest $200 million in Gujarat-based medtech co Meril

Time of India

time3 hours ago

  • Time of India

ADIA to invest $200 million in Gujarat-based medtech co Meril

Ahmedabad: Abu Dhabi Investment Authority (ADIA) on Sunday announced it has signed definitive agreements to invest USD 200 million (approximately Rs 1,723 crore) in Gujarat-based medical devices manufacturer Meril, acquiring close to a 3% stake. The transaction values Meril at $6.6 billion (around Rs 56,859 crore). The deal awaits regulatory approval from the Competition Commission of India (CCI). The investment marks ADIA's latest play in India's expanding medical devices manufacturing space. Following the completion of the deal, Meril will be backed by two prominent global investors - ADIA and Warburg Pincus , which had earlier invested in the company. Founded by the Bilakhia Group, Meril is headquartered in Vapi, where it operates a 100-acre, vertically integrated MedTech campus powered entirely by green energy. The company develops and manufactures a range of clinically advanced products including cardiovascular devices, structural heart solutions, surgical robotics, orthopaedic implants, in-vitro diagnostics, and endo-surgery technologies. By far, Meril has invested Rs 1,400 crore in its Vapi facility. In Dec 2024, the company also inaugurated its new medical devices plant in Vapi. Meril exports its products to over 150 countries through a network of more than 35 subsidiaries. The company employs over 13,000 people globally and operates 12 international training academies, where it trains more than 10,000 healthcare professionals annually. tnn

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store